Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Articles

Page Path
HOME > Intest Res > Volume 15(3); 2017 > Article
Original Article Ophthalmologic manifestations in patients with inflammatory bowel disease
Hye Jin Lee1, Hyun Joo Song2, Jin Ho Jeong1, Heung Up Kim2, Sun-Jin Boo2, Soo-Young Na2
Intestinal Research 2017;15(3):380-387.
DOI: https://doi.org/10.5217/ir.2017.15.3.380
Published online: June 12, 2017

1Department of Ophthalmology, Jeju National University School of Medicine, Jeju, Korea.

2Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.

Correspondence to Hyun Joo Song, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, 15 Aran 13-gil, Jeju 63241, Korea. Tel: +82-64-754-8142, Fax: +82-64-717-1131, songhj@jejunu.ac.kr
• Received: August 30, 2016   • Revised: November 3, 2016   • Accepted: November 22, 2016

© Copyright 2017. Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 6,110 Views
  • 96 Download
  • 19 Web of Science
  • 17 Crossref
  • 18 Scopus
Full Article

Download PDF Download PDF

  • Background/Aims
    Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), has been reported to have various ophthalmologic manifestations. The aim of this study was to evaluate the prevalence of ophthalmologic manifestations associated with IBD in Korea.
  • Methods
    Sixty-one patients were examined between May 2013 and October 2014. We performed complete ophthalmologic examinations.
  • Results
    Findings included 36 patients with CD and 25 with UC. The mean age of the patients was 34±16 years and disease duration was 45.3±23.9 months. Ophthalmologic manifestations were positive in 44 cases. Primary complication was diagnosed in 5 cases, as follows; iritis in 2 cases, episcleritis in one case, iritis with optic neuritis in 1 case, and serous retinal detachment in 1 case, without secondary complications. The most common coincidental complication was dry eye syndrome (DES), in 35 patients (57.4%). The prevalence of DES in the control group was 21.3%. The proportion of DES in patients with IBD was significantly higher than in the control group (P=0.002).
  • Conclusions
    Ophthalmologic manifestations were high (72.1%) in IBD patients. Clinically significant primary ocular inflammation occurred in 8.2% of patients. The most common complication was DES. There was a higher rate of DES in patients with IBD compared to the control group. Evaluation of the eye should be a routine component in patients with IBD.
  • Keywords: Inflammatory bowel disease; Crohn disease; Colitis, ulcerative; Ophthalmology; Dry eye syndromes
Inflammatory bowel disease (IBD) is a chronic disease of unknown cause.1 The prevalence of IBD is higher in North America and Northern Europe, but the incidence and prevalence of IBD has been increasing rapidly in Asia associated with urbanization.1234 Extraintestinal manifestations can occur in the skin, joint, liver, and eye.12
Ophthalmologic complications have been reported with an incidence of 3.5% to 43%.256789 The complications of CD occur frequently.5678 Ophthalmologic complications can be divided into primary, secondary, and coincidental complications.2 Primary complication is related to disease activity, and the condition improved following steroid therapy or surgical treatment. Secondary complications occurred as a result of the primary complications, such as steroid-induced cataract or scleromalacia following scleritis. Coincidental complications include conjunctivitis or dry eye syndrome (DES) found during the regular eye examination, though patients have no prior history of ophthalmologic symptoms. Ophthalmologic complications that are currently recognized include episcleritis, scleritis, cataract, secondary glaucoma, uveitis, and optic neuritis.78
Taylor et al.9 reported that the most common complications are episcleritis, scleritis, and uveitis. Episcleritis occurs in 29% of cases and is the index of disease activity. Scleritis occurs in 18% of cases and uveitis in 17% of cases. Another study reported that episcleritis occurs in 7.7% of cases, uveitis in 11.5% of cases, retinal pigment epithelial detachment in 11.5% of cases and optic neuritis in 3.8% of cases.6 Coincidental DES was found in 50.0% of cases, steroid induced cataract in 30.7% of cases, and conjunctivitis in 3.8% of cases.6
However, the above reports are the result of research in Western countries and, to our knowledge, this study is the first study of its type with Korean patients. Therefore, the aims of the study were to investigate ophthalmologic manifestations in patients with CD and UC in Jeju Island, South Korea, and to determine the necessity of routine eye examination. This is a prospective cross-sectional study of a single institution.
1. Patients Selection
Patients diagnosed with IBD in hospital or outpatient clinic in Division of Gastroenterology between May 2013 and October 2014 were examined in this prospective cross-sectional study. The subjects were included regardless of ocular symptom. Informed consent was obtained from all patients. We surveyed the patients' sex, age, past history, diagnosis of IBD, disease duration, medical treatments, ophthalmologic manifestations or complications and ophthalmologic treatments. All protocols were approved by the Institutional Review Board (IRB) at Jeju National University Hospital (IRB number: 2013-05-011), Jeju, South Korea.
2. Diagnosis of IBD
Four gastroenterologists in Jeju National University Hospital diagnosed IBD according to patients' clinical symptoms, endoscopy findings, imaging and histological examination. CD activity is classified according to CDAI by National Cooperative Crohn's Disease Study.1011 UC is classified according to the Mayo score or the partial Mayo score.1213
3. Ophthalmologic Examination Protocol
One ophthalmologist (H.J.L.) investigated patients' medical and ophthalmologic history and performed the ophthalmologic examinations with consistent testing methods and equipment. Cases including previous ocular trauma and eye surgery including refractive surgery were excluded from this study.
Every patient was measured for uncorrected visual acuity and corrected visual acuity with an early treatment of diabetic retinopathy study (ETDRS) 4-meter visual acuity chart (ETDRS chart R®; Precision Vision, La Salle, USA). They were also measured in each eye for intraocular pressure by non-contact tonometer (KT 800®; Kowa, Tokyo, Japan). Slit lamp biomicroscopic examination was performed on the eyelid, cornea, conjunctiva, sclera, episclera, anterior chamber, lens, and anterior vitreous state. Using non-mydriatic fundus camera (VX 10®; Kowa), the shape and color of the optic nerve and retina were examined. The presence of chorioretinitis, retinal detachment, and retinal pigment epithelium abnormalities were also assessed. When abnormalities of the retina or optic nerve were suspected because of atypical findings in the fundus, mydriatics were instilled in both eyes, and the retina was re-examined with indirect ophthalmoscopy. As needed, fluorescein angiography (Visucam NM/FA®; Carl Zeiss Meditec, Thüringen, Germany) or optical coherent tomography (CirrusHD-OCT4000®; Carl Zeiss Meditec, Dublin, CA, USA) was performed to diagnose ophthalmologic disease. Direct pupillary light reflex was inspected using a swing flashlight test for relative afferent pupillary defect, and if needed, Ishihara color vision test (Ishihara's test for color deficiency, 24 plates edition® 2005; Kanehara & Co., Ltd., Tokyo, Japan) was performed to determine optic nerve dysfunction.
DES was diagnosed according to the criteria of The Korean Corneal Disease Study Group, which included: (1) subjective symptoms: dryness, foreign body sensation, pain, burning sensation, blurring; (2) objective findings: tear breakup time (TBUT) test less than 5 seconds or less than 5 mm on Schirmer test I, or the presence of corneal staining using fluorescent paper and severity of corneal epithelial punctate erosion based on Oxford grading.1415 DES was diagnosed when there was at least one kind of subjective symptom and more than one objective finding.15 Diagnosis of DES was excluded if only subjective symptoms and no objective findings were present.
In testing for TBUT, fluorescein (Fluorescein Paper Strip®; Haag-Streit AG, Koeniz, Switzerland) was smeared into the lower fornix. The patient was asked to blink 3 times and then stop. The time between the last blink and the first appearance of a black spot on the cornea was measured using slit lamp biomicroscopy with a cobalt blue filter setting. In this study, TBUT was measured twice and the average value was used.
Using the Schirmer test I, after asking the patient to look forward without topical anesthetic eye drops, 5 mm×35 mm-sized standard filter paper (Whatman filter paper no. 41) was folded 5 mm from one end and kept in the lower fornix at the junction of lateral third and medial two-thirds. The patient was asked to close their eyes. After 5 minutes, the paper was removed and the length of wetness was measured, using a pre-marked millimeter ruler.
If an ophthalmologic disease was present, treatment was applied and patients were re-examined to determine the improvement of the disease.
4. Setting the Control Group of DES
As previous reports revealed that patients with IBD had significantly high proportion of DES,616 in this study, the control group was set to compare the prevalence of DES between IBD patients and with a control group. The control group included patients with decreased visual acuity due to refractive errors, and patients for counseling of refractive surgery. No patients had a history of systemic disease accompanying DES, were taking medications that could cause DES, or had previously undergone ocular surgery. Medical and ophthalmologic history was assessed, and ophthalmologic examinations were performed on 61 patients in the control group using the same test method with the same diagnostic criteria as described.
5. Statistical Analysis
The data were analyzed using PASW Statistics 18.0 (IBM Corp., Armonk, NY, USA). Patients' age, sex, and the presence or absence of complications was expressed as average and percentage. Continuous variables were described as mean and SD, and paired Student t-test was used for comparison. The chi-square test (Fisher exact test was used for 5 or fewer patients) was used to compare for nominal variables. A P-value of less than 0.05 was considered statistically significant.
1. Patients
Among the 61 patients (37 males, 24 females) with IBD, CD was measured in 36 patients (59.0%), and UC was measured in 25 patients (41.0%). The mean age was 34 years (range, 13–77 years), and the average duration of the disease was 45.3 months (range, 2–264 months). The mean age of UC patients (44 years) was higher than that of CD patients (27 years), which was statistically significant (P=0.003). In this study, 36 patients (59.0%) were in remission, while 14 patients (23.0%) were mild and 11 patients (18.0%) were moderate to severe. There was no difference between CD and UC in the proportion of severity.
The proportion of azathioprine for treatment in patients with CD (77.8%) was higher than that in patients with UC (36.0%) (P=0.004). With the exception of age and usage of azathioprine, there was no statistically significant difference between the 2 groups (Table 1).
2. Ophthalmologic Manifestations
Ophthalmologic manifestations in patients with IBD were found in 44 patients (72.1%, 25 CD and 19 UC). Sixteen patients had more than 1 ocular manifestation. Twenty-five patients were male and, 19 patients were female. There were no differences in the frequency of accompanying ocular manifestations between CD and UC. The most common primary complication that could cause ocular pain or loss of vision was iritis which appeared in 3 cases, followed by episcleritis in 1 patient, optic neuritis in 1 patient, and serous retinal detachment in 1 case (Table 2). All 3 patients with iritis had monocular iritis; one, a 76-year-old woman with UC, had monocular iritis. However, we suspected that the iris pigments were observed from the anterior surface of the lens in both eyes were the cause of chronic alternating iris inflammation (Fig. 1). One patient had both iritis and optic neuritis, therefore, 5 patients (8.2%) were diagnosed with primary complication. There was no patient with secondary complication in this study. The most common coincidental complication was DES appearing in 35 patients, followed by blepharitis in 15 patients, incidentally found cataract in 4 patients, and chorioretinal scar, which was the suspected cause of prior chorioretinitis in 3 patients.
3. Dry Eye Syndrome
Thirty-five patients with IBD (57.4%) were diagnosed with DES. Twenty patients had CD and, 15 patients had UC. In the control group, 13 patients (21.3%) were diagnosed with DES. There was no statistically significant difference between the patients with IBD and the control group in terms of age and sex ratio (Table 3). However, the proportion of DES in case of IBD was statistically significant higher than in the control group (57.4% vs. 21.3%, P=0.002).
4. Ophthalmologic Treatments
Ocular treatments at the time of initial presentation were needed for 24 patients (13 CD and 11 UC, 15 male and 9 female). The mean age of these patients was 35 years. Three of these patients used steroid eyedrops for the treatment of primary complication such as iritis or episcleritis. Six of 8 patients with blepharitis had DES and they were treated with both antibiotic eyedrops and artificial tears (Table 4).
Prevalence of IBD is higher in Western countries, but in recent years, the incidence of IBD has been increasing in South Korea.4 Because of the unknown cause and pathophysiology of the disease, it is fairly difficult to determine the correlation between IBD and ophthalmologic complications associated with specific ophthalmologic disease.1617 Several studies in countries outside of Asia have reported ophthalmologic complications with an incidence of 3.5% to 43%.56789 Only a few studies were performed in a single center (Table 5).61618 The results of those single center studies, including the present study, were divided into primary, secondary, and coincidental complications , as in the case of Knox et al.2
Felekis et al.6 conducted a study in Greece with 60 patients who had IBD and 26 patients (43%) had eye complications (14 CD and 12 UC, 12 male and 14 female). The most common primary complications, as in the case of Knox et al.,2 were iritis and retinal pigment epithelium detachment in 5.0% of cases, which was followed by episcleritis in 3.3% of cases, serous retinal detachment in 3.3% of cases and optic neuritis in 1.7% of cases. Secondary complications of steroid-induced cataract were observed in 8 cases (13.3%). Compared to this, the Greek study showed a higher incidence of primary and secondary complications than the in the present study. DES was the most common coincidental complication, as found in 13 of 26 patients (50%). In 276 persons of the control group (90 male, 186 female; average age, 51.9 years), the prevalence of DES was 11%. The prevalence of DES in patients with IBD was higher than that of the control group.
In a Brazilian study, 112 patients including 24 patients in the control group were enrolled in a community-based cohort study by Cury and Moss.16 Primary complications, including uveitis in 1.8% of cases and episcleritis in 0.9% of cases, were found. Forty-three percent of the patients with IBD were diagnosed with DES compared to the control group, where it occurred in 12% of cases. The research hypothesized that the use of 5-aminosalicylic acid (ASA) exceeding 3 g per day might be associated with the high prevalence of DES. In this study, 5-ASA was used in 91.8% of cases, but it was difficult to prove an association with DES because of its cross-sectional nature. In another prospective study undertaken in Turkey, 116 patients with IBD were given ophthalmological examinations every month for 12 months.18 Thirty-four patients (29.3%) had ophthalmologic complications, which appeared often in CD (CD 60.0%, UC 22.9%) patients. The most common primary complication was uveitis in 5.2% of patients followed by episcleritis in 3.5% of patients. Cataracts were observed as a secondary complication in 5.2% of patients. The coincidental complication was conjunctivitis in 8.6% of patients, followed by blepharitis in 6.9% of patients. A survey for DES was not conducted.
In this study, 61 patients were targeted, and 61 were recruited as a control group for DES. Forty-four patients (72.1%) had ophthalmologic manifestations, a higher incidence compared to other studies.6718 Primary complications were diagnosed in 5 cases (8.2%), iritis in 2 cases (3.3%), episcleritis in 1 case (1.6%), both iritis and optic neuritis in 1 case (1.6%) and serous retinal detachment in 1 case (1.6%). In addition to this, 3 patients had chorioretinal scarring, which caused us to suspect this as the cause of the history of chorioretinitis, while another 3 patients (4.9%) showed iris pigments on the anterior lens surface without active inflammation in the anterior chamber, with suspected history of iritis. If this was a large cohort study, the prevalence of primary complications might be higher.
However, secondary ophthalmologic complications, such as steroid-induced cataract, glaucoma, or scleromalacia, were not found. It can be speculated that the small number of patients with a short follow-up period result from the prospective cross-sectional study. This may also have been due to the small number of patients using corticosteroids (29, 47.5%) with short-term use and mild disease activity.
The most common coincidental complication was DES in 35 patients (57.4%), followed by blepharitis in 24.6% of cases. There was no difference between CD and UC with regard to the incidence of ophthalmologic complications (Table 2). Four patients, coincidentally-diagnosed with cataracts, did not include steroid-induced posterior subcapsular cataract: 3 patients with senile nucleosclerosis and 1 patient with anterior cortical cataract. Jobling and Augusteyn19 emphasized that care should be taken when using steroids because steroid-induced cataracts tend to occur in proportion to the total amount of corticosteroid. In children, in particular, at lower amounts of steroid, steroid-induced cataracts occurred faster. Therefore, when using corticosteroids in patients with IBD, the possibility of cataracts should be explained and regular eye examinations should be recommended.
The incidence of DES in this study was similar to other studies (43%–50%).616 It is important to note the interpretation of the results concerning the incidence of DES, as the diagnostic criteria for each study were slightly different from one other. In the Greek study, 3 ophthalmologic examinations were performed: (1) 10 seconds or less in TBUT, (2) more than 3 points after staining with Rose Bengal dye, and (3) less than 5.5 mm after 5 minutes in the Schirmer test I. In that study, DES was defined as abnormal if any of the 3 above were found.6 In Brazil, abnormality was defined as 10 seconds or less in TBUT, more than 3 points after staining with Rose Bengal dye, less than 10 mm after 5 minutes in the Schirmer test I. DES was diagnosed when 2 or more of the above were found. However, the Brazilian study had a problem in the small number (only 24 participants) of the control group.16 Although the diagnostic criteria in this study were more stringent than in the previous 2 reports,616 the prevalence of DES in control group appeared as 11% in Greece,6 12% in Brazil,16 and 21% in this study. Comparatively, the Korean study appeared to have a relatively high proportion of DES. However, the control group included persons who were examined for refractive surgery and typically had used contact lenses previously. DES can be induced by contact lenses, so there might be a selection bias, which caused the error to be exaggerated.
To date, episcleritis, scleritis and iritis have been known to occur in association with disease activity of IBD according to previous studies.3469 Among 5 patients with primary complication in this study, 1 patient with episcleritis and, 2 of 3 patients with iritis had mild disease activity, while another patient with both iritis and optic neuritis was in a state of remission. Only 1 patient with serous chorioretinal detachment in UC had severe disease activity (Table 6). Cury and Moss's research16 demonstrated a rate of 1.8% of uveitis and 0.9% of episcleritis, though the patients who ranked over 250 on the CDAI with CD and moderate or severe in Truelove and Witt's activity with UC totaled 59% of all patients. In this study, most primary complication occurred in patients in remission or with mild disease activity.
This study has some limitations. The number of patients with IBD was insufficient. Patient disease activity was stabilized following long-term medication after being previously diagnosed in the division of gastroenterology. As UC patients tend toward a low percentage of admission, because symptoms of UC are mild, many patients without ocular symptoms often refused ophthalmologic tests. The annual incidence of Korean patients with IBD is 0.34 per 100,000 people in CD, and 3.08 persons in UC.4 The incidence of UC is greater than CD. However, in this study, the percentage of patients with CD was higher than that with UC. The results could be influenced by the high proportion of young patients, short average disease duration, short term follow-up duration, mild clinical aspects and good response to medication for IBD in Korean patients.17 A greater number of patients will be needed for long-term follow-up research with regular (defined as, every 1 or 2 months) eye examinations. Moreover, future research of the correlation between ophthalmologic complications and disease activity, prevalence of secondary complications, such as steroid-induced cataract or glaucoma, and the relevance of medication and ophthalmologic complication is necessary. In addition, further investigations of patients with ocular symptoms in the active phase should be conducted. Despite the limitations in this study, this is the first prospective cross-sectional study in a single center in South Korea.
In conclusion, ophthalmologic complications occurred in 72.1% of patients with IBD. Patients with IBD had primary complications that could cause ocular pain or visual loss in 8.2% of cases. There was no secondary complication. The most common coincidental complication was DES, the prevalence of which was higher than in the control group. Although DES rarely causes severe visual loss, it can cause ocular discomfort and a lower quality of life. By ocular examination and treatment, it is possible to reduce the symptoms of DES in IBD patients. Therefore, a thorough ophthalmologic examination at the time of diagnosis of IBD should be a routine component. In addition, regular ophthalmologic examination of patients without ocular symptoms can help prevent irreversible visual loss through early detection and treatment.

Financial support: This work was supported by the research grant of Jeju National University Hospital in 2013.

Conflict of interest: None.

  • 1. Ernst BB, Lowder CY, Meisler DM, Gutman FA. Posterior segment manifestations of inflammatory bowel disease. Ophthalmology 1991;98:1272–1280.PMID: 1923366.ArticlePubMed
  • 2. Knox DL, Schachat AP, Mustonen E. Primary, secondary and coincidental ocular complications of Crohn's disease. Ophthalmology 1984;91:163–173.PMID: 6538677.ArticlePubMed
  • 3. Hu PJ. Inflammatory bowel disease in Asia: the challenges and opportunities. Intest Res 2015;13:188–190.PMID: 26130991.ArticlePubMedPMC
  • 4. Lee JW, Im JP, Cheon JH, Kim YS, Kim JS, Han DS. Inflammatory bowel disease cohort studies in Korea: present and future. Intest Res 2015;13:213–218.PMID: 26130995.ArticlePubMedPMC
  • 5. Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv Ophthalmol 2003;48:663–676.PMID: 14609712.ArticlePubMed
  • 6. Felekis T, Katsanos K, Kitsanou M, et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis 2009;15:29–34.PMID: 18626979.ArticlePubMed
  • 7. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982–1992.PMID: 26154136.ArticlePubMedPMC
  • 8. Thomas AS, Lin P. Ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol 2016;27:552–560.PMID: 27585211.ArticlePubMed
  • 9. Taylor SR, McCluskey P, Lightman S. The ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol 2006;17:538–544.PMID: 17065922.ArticlePubMed
  • 10. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77(4 Pt 2): 829–842.PMID: 38175.ArticlePubMed
  • 11. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2): 11–17.PMID: 12786607.ArticlePubMed
  • 12. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–786.PMID: 17258735.ArticlePubMed
  • 13. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660–1666.PMID: 18623174.ArticlePubMedPMC
  • 14. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640–650.PMID: 14508260.ArticlePubMed
  • 15. Hyon JY, Kim HM, Lee D, et al. Korean guidelines for the diagnosis and management of dry eye: development and validation of clinical efficacy. Korean J Ophthalmol 2014;28:197–206.PMID: 24882952.ArticlePubMedPMC
  • 16. Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1393–1396.PMID: 19998457.ArticlePubMed
  • 17. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010;4:1–14.PMID: 20479907.ArticlePubMedPMC
  • 18. Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis 2007;22:1027–1030.PMID: 17262200.ArticlePubMed
  • 19. Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 2002;85:61–75.PMID: 11952401.ArticlePubMed
Fig. 1

Anterior segment photograph of a 76-year-old female patient with UC. This picture shows severe iritis in the left eye.

ir-15-380-g001.jpg
Table 1

Demographic Characteristics of 61 IBD Patients Who Underwent Ophthalmologic Examination

ir-15-380-i001.jpg
Characteristic Total (n=61) CD (n=36) UC (n=25) P-value
Age (yr) 34±16 27±13 44±15 0.003
Male sex 37 (60.7) 25 (69.4) 12 (48.0) 0.092
Disease duration (mo) 45.3±23.9 37.1±20.3 57.2±32.7 0.102
Disease activitya
 Remission 36 (59.0) 23 (63.9) 13 (52.0) 0.353
 Mild 14 (23.0) 10 (27.8) 4 (16.0) 0.362
 Moderate 10 (16.4) 3 (8.3) 7 (28.0) 0.075
 Severe 1 (1.7) 0 1 (4.0) 0.410
Treatment
 5-ASA 56 (91.8) 34 (94.4) 22 (88.0) 0.374
 Corticosteroid 29 (47.5) 16 (44.4) 13 (52.0) 0.557
 Azathioprine 37 (60.7) 28 (77.8) 9 (36.0) 0.004
 Infliximab 10 (16.4) 6 (16.7) 4 (16.0) 0.935
No. of patients with ocular manifestations 44 (72.1) 25 (69.4) 19 (76.0) 0.571
Ocular treatmentb 24 (39.3) 13 (36.1) 11 (44.0) 0.398

Values are presented as mean±SD or number (%).

aCD, CDAI; UC, Mayo or partial Mayo score.

bNeed for ocular treatment at the initial presentation.

5-ASA, 5-aminosalicylic acid.

Table 2

Ophthalmologic Manifestations of IBD Patients

ir-15-380-i002.jpg
Total (n=61) CD (n=36) UC (n=25) P-value
Primary complication
 Iritis 3 (4.9) 2 (5.6) 1 (4.0) 1
 Episcleritis 1 (1.6) 1 (2.8) 0 1
 Optic neuritis 1 (1.6) 1 (2.8) 0 1
 Serous RD 1 (1.6) 0 1 (4.0) 0.407
Coincidental complication
 Dry eye syndrome 35 (57.4) 20 (55.6) 15 (60.0) 0.731
 Blepharitis 15 (24.6) 7 (19.4) 8 (32.0) 0.258
 Cataract 4 (6.6) 2 (5.6) 2 (8.0) 1
 Chorioretinal scar 3 (4.9) 1 (2.8) 2 (8.0) 0.556

Values are presented as number (%).

RD, retinal detachment.

Table 3

Comparison of Dry Eye Syndrome between IBD Patients and Healthy Control Groups

ir-15-380-i003.jpg
IBD (n=61) Control (n=61) P-value
Age (yr) 35±15 33±10 0.506
Male sex 37 (60.7) 30 (49.2) 0.275
Prevalence 35 (57.4) 13 (21.3) 0.002

Values are presented as mean±SD or number (%).

Table 4

Treatments of Ophthalmologic Complications

ir-15-380-i004.jpg
No. of patients (%) Treatment
Primary complication
 Iritis 2 (4.5) Steroid eyedrops
 Episcleritis 1 (2.3) Steroid eyedrops
Coincidental complication
 Dry eye syndrome 19 (43.2) Artificial tears
 Blepharitis 8 (18.2) Antibiotic eyedrops
Table 5

Comparison of Ophthalmologic Complications among Single Center Studies

ir-15-380-i005.jpg
Author (year) Country No. of patients (CD/UC) Male sex (%) Average age (yr) Ocular complication (%) Most common complication DES in IBD (%) No. of controls DES in control (%)
Felekis et al. (2009)6 Greece 60 (23/37) 53 50 43 DES 22 276 11
Cury and Moss (2010)16 Brazil 88 (48/40) 38 41 59 DES 43 24 12
Yilmaz et al. (2007)18 Turkey 116 (20/96) 60 41 29 Conjunctivitis NA NA NA
Current study South Korea 61 (36/25) 61 34 72 DES 57 61 21

DES, dry eye syndrome; NA, not applicable.

Table 6

Primary Ocular Complications According to IBD Activity

ir-15-380-i006.jpg
CD according to CDAI (n=36) No. of CD patients UC according to Mayo or partial Mayo score (n=25) No. of UC patients
Remission 1 With iritis and optic neuritis 23 0 13
Mild 1 With episcleritis, 1 with iritis 10 1 With iritis 4
Moderate 0 3 0 7
Severe 0 0 1 With serous retinal detachment 1

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Isoliquiritin Ameliorates Ulcerative Colitis in Rats through Caspase 3/HMGB1/TLR4 Dependent Signaling Pathway
      Zhiwei Miao, Mingjia Gu, Faisal Raza, Hajra Zafar, Jianyi Huang, Yuhang Yang, Muhammad Sulaiman, Jing Yan, Yi Xu
      Current Gene Therapy.2024; 24(1): 73.     CrossRef
    • Use of Systemic Steroids for Inflammatory Bowel Disease Can Increase Intraocular Pressure
      Amrik Gil, Madeline Alizadeh, Daniel Yarmovsky, Ramya Swamy, Uni Wong
      Gastro Hep Advances.2024; 3(4): 536.     CrossRef
    • Ocular lesions in patients with ulcerative colitis
      Antonina V. Varvarynets, Valerii D. Beliayev, Mykhailo M. Hechko, Artur V. Kurakh
      Wiadomości Lekarskie.2024; 77(3): 445.     CrossRef
    • The risk for ophthalmological conditions in ulcerative colitis: A population‐based case–control study. Is silica dust‐exposure associated with inflammatory eye disease?
      Karim Makdoumi, Lucyn Ayoub, Ing‐Liss Bryngelsson, Pål Graff, Pernilla Wiebert, Per Vihlborg
      Acta Ophthalmologica.2024; 102(7): 828.     CrossRef
    • Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
      Yakup Kilic, Shahed Kamal, Farah Jaffar, Danujan Sriranganathan, Mohammed Nabil Quraishi, Jonathan P Segal
      Inflammatory Bowel Diseases.2023;[Epub]     CrossRef
    • Optical coherence tomography angiography findings of retinal vascular structures in children with celiac disease
      Ishak Isik, Lutfiye Yaprak, Asli Yaprak, Ulas Akbulut
      Journal of American Association for Pediatric Ophthalmology and Strabismus.2022; 26(2): 69.e1.     CrossRef
    • Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era
      Alix Cuny, Lucas Guillo, Cédric Baumann, Patrick Netter, Silvio Danese, Bénédicte Caron, Laurent Peyrin-Biroulet, Karine Angioi
      Journal of Clinical Medicine.2022; 11(15): 4538.     CrossRef
    • The Prevalence of Ocular Extra-Intestinal Manifestations in Adults Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
      Jing-Xing Li, Chun-Chi Chiang, San-Ni Chen, Jane-Ming Lin, Yi-Yu Tsai
      International Journal of Environmental Research and Public Health.2022; 19(23): 15683.     CrossRef
    • Ocular Manifestations of Inflammatory Bowel Disease
      Janaki Shah, Aaditya Shah, Lynn Hassman, Alexandra Gutierrez
      Inflammatory Bowel Diseases.2021; 27(11): 1832.     CrossRef
    • Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists
      Fabio CASTELLANO, Giovanni ALESSIO, Carmela PALMISANO
      Minerva Gastroenterology.2021;[Epub]     CrossRef
    • The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)—A Critical Review
      Dominika Jakubczyk, Katarzyna Leszczyńska, Sabina Górska
      Nutrients.2020; 12(7): 1973.     CrossRef
    • Les manifestations oculaires au cours de la maladie de Crohn
      D. Saadouli, K. Ben Mansour, M. Farae, I. Loukil, S. Yahyaoui, M.A. El Afrit
      Journal Français d'Ophtalmologie.2020; 43(10): 1025.     CrossRef
    • Evaluation of Objective Signs and Subjective Symptoms of Dry Eye Disease in Patients with Inflammatory Bowel Disease
      Zsolt Barta, Levente Czompa, Aniko Rentka, Eva Zold, Judit Remenyik, Attila Biro, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
      BioMed Research International.2019; 2019: 1.     CrossRef
    • The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
      Ana Luiza Biancardi, Leandro Lopes Troncoso, Haroldo Vieira de Moraes Jr, Cyrla Zaltman
      Intestinal Research.2019; 17(1): 153.     CrossRef
    • Current clinical issue of skin lesions in patients with inflammatory bowel disease
      Tomoya Iida, Tokimasa Hida, Minoru Matsuura, Hisashi Uhara, Hiroshi Nakase
      Clinical Journal of Gastroenterology.2019; 12(6): 501.     CrossRef
    • Manifestaciones extraintestinales de enfermedad inflamatoria intestinal
      Amaranta Luzoro, Pablo Sabat, Leonardo Guzmán, Francisca Frias
      Revista Médica Clínica Las Condes.2019; 30(4): 305.     CrossRef
    • Corneal Manifestations of Inflammatory Bowel Disease
      Levente Czompa, Zsolt Barta, Hassan Ziad, Gabor Nemeth, Aniko Rentka, Zsuzsa Aszalos, Eva Zold, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
      Seminars in Ophthalmology.2019; 34(7-8): 543.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Ophthalmologic manifestations in patients with inflammatory bowel disease
      Intest Res. 2017;15(3):380-387.   Published online June 12, 2017
      DOI: https://doi.org/10.5217/ir.2017.15.3.380
      Close
    • XML DownloadXML Download
    Figure
    • 0
    Related articles
    Ophthalmologic manifestations in patients with inflammatory bowel disease
    Image
    Fig. 1 Anterior segment photograph of a 76-year-old female patient with UC. This picture shows severe iritis in the left eye.

    Fig. 1

    Ophthalmologic manifestations in patients with inflammatory bowel disease

    Demographic Characteristics of 61 IBD Patients Who Underwent Ophthalmologic Examination

    CharacteristicTotal (n=61)CD (n=36)UC (n=25)P-value
    Age (yr)34±1627±1344±150.003
    Male sex37 (60.7)25 (69.4)12 (48.0)0.092
    Disease duration (mo)45.3±23.937.1±20.357.2±32.70.102
    Disease activitya
     Remission36 (59.0)23 (63.9)13 (52.0)0.353
     Mild14 (23.0)10 (27.8)4 (16.0)0.362
     Moderate10 (16.4)3 (8.3)7 (28.0)0.075
     Severe1 (1.7)01 (4.0)0.410
    Treatment
     5-ASA56 (91.8)34 (94.4)22 (88.0)0.374
     Corticosteroid29 (47.5)16 (44.4)13 (52.0)0.557
     Azathioprine37 (60.7)28 (77.8)9 (36.0)0.004
     Infliximab10 (16.4)6 (16.7)4 (16.0)0.935
    No. of patients with ocular manifestations44 (72.1)25 (69.4)19 (76.0)0.571
    Ocular treatmentb24 (39.3)13 (36.1)11 (44.0)0.398

    Values are presented as mean±SD or number (%).

    aCD, CDAI; UC, Mayo or partial Mayo score.

    bNeed for ocular treatment at the initial presentation.

    5-ASA, 5-aminosalicylic acid.

    Ophthalmologic Manifestations of IBD Patients

    Total (n=61)CD (n=36)UC (n=25)P-value
    Primary complication
     Iritis3 (4.9)2 (5.6)1 (4.0)1
     Episcleritis1 (1.6)1 (2.8)01
     Optic neuritis1 (1.6)1 (2.8)01
     Serous RD1 (1.6)01 (4.0)0.407
    Coincidental complication
     Dry eye syndrome35 (57.4)20 (55.6)15 (60.0)0.731
     Blepharitis15 (24.6)7 (19.4)8 (32.0)0.258
     Cataract4 (6.6)2 (5.6)2 (8.0)1
     Chorioretinal scar3 (4.9)1 (2.8)2 (8.0)0.556

    Values are presented as number (%).

    RD, retinal detachment.

    Comparison of Dry Eye Syndrome between IBD Patients and Healthy Control Groups

    IBD (n=61)Control (n=61)P-value
    Age (yr)35±1533±100.506
    Male sex37 (60.7)30 (49.2)0.275
    Prevalence35 (57.4)13 (21.3)0.002

    Values are presented as mean±SD or number (%).

    Treatments of Ophthalmologic Complications

    No. of patients (%)Treatment
    Primary complication
     Iritis2 (4.5)Steroid eyedrops
     Episcleritis1 (2.3)Steroid eyedrops
    Coincidental complication
     Dry eye syndrome19 (43.2)Artificial tears
     Blepharitis8 (18.2)Antibiotic eyedrops

    Comparison of Ophthalmologic Complications among Single Center Studies

    Author (year)CountryNo. of patients (CD/UC)Male sex (%)Average age (yr)Ocular complication (%)Most common complicationDES in IBD (%)No. of controlsDES in control (%)
    Felekis et al. (2009)6Greece60 (23/37)535043DES2227611
    Cury and Moss (2010)16Brazil88 (48/40)384159DES432412
    Yilmaz et al. (2007)18Turkey116 (20/96)604129ConjunctivitisNANANA
    Current studySouth Korea61 (36/25)613472DES576121

    DES, dry eye syndrome; NA, not applicable.

    Primary Ocular Complications According to IBD Activity

    CD according to CDAI (n=36)No. of CD patientsUC according to Mayo or partial Mayo score (n=25)No. of UC patients
    Remission1 With iritis and optic neuritis23013
    Mild1 With episcleritis, 1 with iritis101 With iritis4
    Moderate0307
    Severe001 With serous retinal detachment1
    Table 1 Demographic Characteristics of 61 IBD Patients Who Underwent Ophthalmologic Examination

    Values are presented as mean±SD or number (%).

    aCD, CDAI; UC, Mayo or partial Mayo score.

    bNeed for ocular treatment at the initial presentation.

    5-ASA, 5-aminosalicylic acid.

    Table 2 Ophthalmologic Manifestations of IBD Patients

    Values are presented as number (%).

    RD, retinal detachment.

    Table 3 Comparison of Dry Eye Syndrome between IBD Patients and Healthy Control Groups

    Values are presented as mean±SD or number (%).

    Table 4 Treatments of Ophthalmologic Complications

    Table 5 Comparison of Ophthalmologic Complications among Single Center Studies

    DES, dry eye syndrome; NA, not applicable.

    Table 6 Primary Ocular Complications According to IBD Activity

    Table 1

    Table 2

    Table 3

    Table 4

    Table 5

    Table 6

    Intest Res : Intestinal Research
    © Korean Association for the Study of Intestinal Diseases.
    Close layer
    TOP